Trial
NCT03599362
Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
NYU Langone Health
Collaborators
—
Condition
Pancreatic Cancer
Intervention
Nivolumab + Cabiralizumab
Why stopped
PI departure from institution
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-19